Maintenance therapy by vaginal progesterone after threatened idiopathic preterm labor: A randomized placebo-controlled double-blind trial

International Journal of Fertility and Sterility

Volumn 4, Issue 2, 2010, Pages 45-50

  Sharami, Seyede Hajar ^a   Zahiri, Ziba ^a   Shakiba, Maryam ^b,c   Milani, Frozan ^b  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Mehr Infertility Institute   (Iran)

Author keywords

Preterm birth; Preterm labor; Progesterone; Vaginal tablet

Indexed keywords

PLACEBO; PROGESTERONE;

ADULT; APGAR SCORE; ARTICLE; BIRTH WEIGHT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GESTATION PERIOD; GESTATIONAL AGE; HEADACHE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; NAUSEA; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN DEATH; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; PREECLAMPSIA; PREGNANT WOMAN; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURE LABOR; RANDOMIZED CONTROLLED TRIAL; SUPPOSITORY; TREATMENT OUTCOME; UTERUS CONTRACTION;

EID: 77957338402     PISSN: 2008076X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Villar J, Abalos E, Carroli G, Giordano D, Wojdyla D, Piaggio G, et al. World Health Organization Antenatal Care Trial Research Group. Hetreogenesity of perinatal outcomes in the preterm delivery syndrome. Obstet Gynecol. 2004; 104: 78-87.
2. Mattison DR, Damus K, Fioer E, Petrini J, Alter C. Preterm delivery: a public health prespective. Paediatr Perinat Epidemiol. 2001; 15 suppl 2: 7-16.
3. Amon E, Preterm labor. In: Reece EA, Hobbins JC, editors. Medicine of the fetus and mothers. Philadelphia: Lippincott-Raven; 1999; 1529-1579.
4. Schindler AE. Role of progestogens for the prevention of premature birth. J Steroid Biochem Mol Biol. 2005; 97(5): 435-438.
5. Ehrenhaft PM, Wagner JL, Herdman RC. Changing prognosis for very low birth weight infants. Obstet Gynecol. 1989; 74(3 pt 2): 528-535.
6. nd ed. New York: McGRAW-HILL, Medical Publishing Division; 2005; 855-873.
7. Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003; 188(2): 419-424.
8. Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2008; 48(1): 58-63.
9. Facchinetti F, Dante G, Venturini P, Paganelli S, Volpe A. 17alpha-hydroxy-progesterone effects on cer-vical proinflammatory agents in women at risk for preterm delivery. Am J perinatol. 2008; 25(8): 503-506.
10. Facchinetti F, Paganelli S, Comitini G, Dante G, Volpe A. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2007; 196(5): 453.
11. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recrrent preterm delivery by 17 alpha-hydroxyprogesrtone caproate. N Engl J Med. 2003; 348: 2379-2385.
12. Meis PJ, Connors N. Progesterone treatment to prevent preterm birth. Clin Obstet Gynecol. 2004; 47(4): 784-795.
13. Chwalisz K, Stöckemann K, Fuhrmann U, Fritzemeier KH, Einspanier A, Garfield RE. Mechanism of action of antiprogestins in the pregnant uterus. Ann NY Acad Sci. 1995; 761: 202-223.
14. Pieber D, Allport VC, Hills F, Johnson M, Bennett PR. Interaction between progestrone receptor isoforms in myometrial cells in human labour. Mol Hum Reprod. 2001; 7: 875-879.
15. Astle S, Slater DM, Thornton S. The involvement of progestrone in the onset of human labour. Eur J Obstet Gynecol Reprod Biol. 2003; 108: 177-181.
16. Grazzini E, Guillon G, Mouillac B, Zingg HH. Inhibation of oxytocin receptor function by direct binding of progestrone. Nature. 1998; 392: 509-512.
17. Smith R, Mesiano S, Nicholson R, Zakar T, Chan E, Bisits A, et al. Control of the length of gestation: lessons from women. In: Critchley H, Bennett P, Thornton S, (eds). Preterm Birth. London: RCOG Publications; 2004.
18. Wieser F, Hosmann J, Tschugguel W, Czerwenka K, Sedivy R, C Huber J. Progesterone increases the number of Langerhans cells in human vaginal epithelium. Fertil Steril. 2001; 75(6): 1234-1235.
19. Thornton JG. Maintenance tocolysis. BJOG. 2005; 112 suppl 1: 118-121.
20. Rouse DJ, Caritis SN, Peaceman AM Sciscione A. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007; 357: 454-461.
21. Chanrachakul B, Pipkin FB, Warren AY, Arulkumaran S, Khan RN. Progesterone enhances the tocolytic effect of ritodrine in isolated pregnant human myometrium. Am J Obstet Gynecol. 2005; 192(2): 458-463.
22. Laskarin G, Tokmadzić VS, Strbo N, Bogović T, Szekeres-Bartho J, Randić L, et al. Progesterone induced blocking factor (PIBF) mediates progesterone induced suppression of decidual lymphocyte cytotoxicity. Am J Reprod Immunol. 2002; 48(4): 201-209.
23. Elovitz M, Wang Z. Medroxyprogestrone acetate, but not progesterone, protects against inflammationinduced parturition and intrauterine fetal demise. Am J Obstet Gynecol. 2004; 190: 693-701.
24. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med. 2007; 357(5):462-9.
25. Dodd JM, Flenady VJ, Cincotta R, Crowther CA. Progesterone for the prevention of preterm birth: a systematic review. Obstet Gynecol. 2008; 112(1): 127-134.
26. Mackenzie R, Walker M, Armson A, Hannah ME. Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol. 2006; 194(5): 1234-1242.